

1           **Transcutaneous auricular vagus nerve stimulation enhanced**  
2           **inhibitory control via increasing intrinsic prefrontal couplings**

3           Siyu Zhu<sup>1,2</sup>, Qi Liu<sup>1</sup>, Xiaolu Zhang<sup>1</sup>, Menghan Zhou<sup>1</sup>, Xinqi Zhou<sup>3</sup>, Fangyuan Ding<sup>4</sup>,  
4           Rong Zhang<sup>5</sup>, Benjamin Becker<sup>6,1</sup>, Keith M Kendrick<sup>1#</sup>, Weihua Zhao<sup>1#</sup>

5           <sup>1</sup> The Center of Psychosomatic Medicine, Sichuan Provincial Center for Mental Health, Sichuan  
6           Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu,  
7           611731, China

8           <sup>2</sup> School of Sport Training, Chengdu Sport University, Chengdu, 610041, China

9           <sup>3</sup> Institute of Brain and Psychological Science, Sichuan Normal University, Chengdu, 610066,  
10          China

11          <sup>4</sup> College of National Culture and Cognitive Science, Guizhou Minzu University, Guiyang,  
12          550025, China

13          <sup>5</sup> Neuroscience Research Institute; Key Laboratory for Neuroscience, Ministry of Education of  
14          China; Key Laboratory for Neuroscience, National Committee of Health and Family Planning of  
15          China; and Department of Neurobiology, School of Basic Medical Sciences, Peking University,  
16          Beijing, 100191, China

17          <sup>6</sup> The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong;  
18          Department of Psychology, The University of Hong Kong, Hong Kong, 999077, China

19  
20          # Corresponding authors at: The Center of Psychosomatic Medicine, Sichuan  
21          Provincial Center for Mental Health, Sichuan Provincial People's Hospital, University  
22          of Electronic Science and Technology of China, Chengdu, 610072, China. E-mail  
23          addresses: k.kendrick.uestc@gmail.com (K.M. Kendrick), zarazhao@uestc.edu.cn (W.  
24          Zhao).

25          # Contributed equally to this work i.e., joint corresponding authors.

26

## 27 **Abstract**

28 Inhibitory control represents a core executive function that critically facilitates  
29 adaptive behavior and survival in an ever-changing environment. Non-invasive  
30 transcutaneous auricular vagus nerve stimulation (taVNS) has been hypothesized to  
31 improve behavioral inhibition performance, however the neurocomputational  
32 mechanism of taVNS-induced neuroenhancement remain elusive. In the current study,  
33 we investigated the effect of taVNS on inhibitory control in a pre-registered  
34 sham-controlled between-subject functional near infrared spectroscopy (fNIRS)  
35 experiment with an emotional face Go/No-Go paradigm in ninety subjects. After data  
36 quality check, eighty-two subjects were included in the final data  
37 analysis. Behaviorally, the taVNS improved No-Go response accuracy, together with  
38 computational modeling using Hierarchical Bayesian estimation of the Drift Diffusion  
39 Model (HDDM) indicating that it specifically reduced the information accumulation  
40 rate for Go responses, and this was negatively associated with increased accuracy of  
41 No-Go responses. On the neural level, taVNS enhanced engagement of the bilateral  
42 inferior frontal gyrus (IFG) during inhibition of angry expression faces and modulated  
43 functional couplings (FCs) within the prefrontal inhibitory control network. Mediation  
44 models revealed that taVNS-induced facilitation of inhibitory control was critically  
45 mediated by a decreased information accumulation for Go responses and  
46 concomitantly enhanced neurofunctional coupling between the inferior and orbital  
47 frontal cortex. Our findings demonstrate a striking potential for taVNS to improve  
48 inhibitory control via reducing pre-potent responses and enhancing FCs within  
49 prefrontal inhibitory control networks, suggesting a promising therapeutic role in  
50 treating specific disorders characterized by inhibitory control deficits.

## 51 **Keywords**

52 Inhibitory control; Transcutaneous auricular vagus nerve stimulation; Computational  
53 modelling; Dynamic functional connectivity; Mediation model

54

## 55 **1. Introduction**

56 Inhibitory control is a core executive function vital for adaptive behavioral regulation  
57 via suppression of inappropriate responses. In everyday life it allows us to control  
58 automatic urges at perceptual, cognitive, and behavioral levels (Diamond, 2013).  
59 Prefrontal cortical (PFC) circuits critically implement inhibitory control on the neural  
60 level (Goldstein *et al.*, 2007), particularly the inferior frontal gyrus (IFG) (Munakata  
61 *et al.*, 2011; Zhuang *et al.*, 2022). Interestingly, deficits in inhibitory control (e.g.  
62 impulsivity, hyperactivity) are the primary transdiagnostic characteristics of  
63 individuals with attention-deficit/hyperactivity disorder (ADHD) (Polanczyk *et al.*,  
64 2007), substance use disorders (Hildebrandt *et al.*, 2021), posttraumatic stress disorder  
65 (PTSD) (Catarino *et al.*, 2015) and obesity (Jasinska *et al.*, 2012). Improving  
66 inhibitory control thus represents a highly promising therapeutic target for clinical  
67 application.

68 Transcutaneous auricular vagus nerve stimulation (taVNS) - a novel  
69 non-invasive neuromodulation technique - has been hypothesized to promote  
70 inhibitory control via its regulation of the locus coeruleus-norepinephrine (LC-NE)  
71 network and GABAergic system (Burger *et al.*, 2020; Zhu *et al.*, 2022b). The LC-NE  
72 network plays a pivotal role in inhibitory control. Accumulating evidence from brain  
73 imaging studies indicates that the neural activity of LC-NE system could modulate  
74 functional connectivity within the prefrontal inhibitory control network (Chamberlain  
75 *et al.*, 2007, 2009; Passamonti *et al.*, 2018; Li *et al.*, 2020; Tomassini *et al.*, 2022).  
76 Recently, one study reported that oral atomoxetine (i.e. a noradrenergic reuptake  
77 inhibitor) improved reaction times during inhibition in Parkinson patients with lower  
78 LC integrity (O'Callaghan *et al.*, 2021). Consistent with this, taVNS has been found  
79 to increase the activation of brainstem regions, including the LC (Frangos *et al.*, 2015;  
80 Yakunina *et al.*, 2017), suggesting a modulatory role of taVNS in inhibitory control  
81 ability via its impact on the LC-NE network. Moreover, the neurotransmitter  
82  $\gamma$ -aminobutyric acid (GABA) also plays a key role in modulating cognitive  
83 performance with demands for inhibitory control. Using magnetic resonance

84 spectroscopy, Hermans and colleagues found that older adults with lower GABA  
85 levels exhibited a prolonged stop-signal responses time (Hermans *et al.*, 2018),  
86 indicating a negative relationship between inhibitory response and GABA levels,  
87 particularly in inferior frontal regions (Murley *et al.*, 2020). More importantly, taVNS  
88 significantly increased GABA-A receptor activity (Capone *et al.*, 2015). Taken  
89 together, these findings suggest that taVNS may be an effective neuromodulator to  
90 improve inhibitory control by regulating activity of the LC-NE network and  
91 GABAergic system.

92 Some initial studies provided preliminary although inconsistent evidence for  
93 beneficial effects of taVNS on inhibitory control. For instance, although Borges et al  
94 (2020) suggested that taVNS can increase cognitive flexibility in a set-shifting task,  
95 no improvement on inhibitory performance in either the Flanker task (i.e. for selective  
96 attention measurement) or in the Spatial Stroop task were found (Borges *et al.*, 2020).  
97 However, it has been subsequently reported that taVNS improved adaption to conflict  
98 in the Simon task (Fischer *et al.*, 2018). Additionally, although some initial behavioral  
99 studies have consistently shown that response inhibition in a Go/No-Go task was  
100 enhanced by active taVNS (Beste *et al.*, 2016; Keute *et al.*, 2020; Pihlaja *et al.*, 2020),  
101 the neural mechanism of the potential beneficial effects of taVNS on inhibition has  
102 not been explored.

103 To better elucidate the potential for taVNS to enhance inhibitory control  
104 performance and the underlying neurocomputational mechanism, we here investigated  
105 the impact of taVNS on inhibition ability in combination with functional near-infrared  
106 spectroscopy (fNIRS). fNIRS is increasingly used as an optical neuroimaging method  
107 based on the hemodynamic response (i.e. concentration of oxygenated hemoglobin;  
108 HbO) due to a higher temporal resolution and lower sensitivity to movement artifacts  
109 which are important for fast response tasks such as the Go/No-Go task (Ferrari and  
110 Quaresima, 2012; Sakai, 2022). In the present study, we adopted a modified  
111 emotional Go/No-Go paradigm with neutral expression faces as Go and emotional  
112 expression faces (i.e., angry and happy faces) as No-Go stimuli. Most importantly, we  
113 further applied a well-validated computational model, the diffusion decision model

114 (DDM), which characterizes within- and between-subject differences in the  
115 Go/No-Go paradigm (Gomez *et al.*, 2007; Zhang *et al.*, 2016; Huang-Pollock *et al.*,  
116 2017; Ratcliff *et al.*, 2018; de Gee *et al.*, 2020; Weigard *et al.*, 2020; Gorka *et al.*,  
117 2022) to fully reveal the critical role of taVNS in modulating inhibitory control  
118 performance from both neurocomputational and behavioral levels. Overall, we  
119 hypothesized that taVNS relative to a sham-control stimulation (earlobe) would  
120 enhance behavioral inhibition in the emotional Go/No-Go task and that this would be  
121 associated with altered neural responses and connectivities in the prefrontal cortex  
122 circuitry important for executive control.

## 123 **2. Materials and methods**

### 124 **2.1. Participants**

125 We recruited 90 healthy adult Chinese university students for the current study with  
126 all reporting being free from medical or psychiatric disorders or current or regular  
127 medication, and who were required not to consume any alcohol, caffeine or nicotine  
128 on the day of the experiment. All participants had normal or corrected to normal  
129 vision. Data from 8 participants were excluded due to not recognizing facial emotions  
130 in the Go/No-Go task (n=5) or technical problems of recording fNIRS data (n=3),  
131 leaving a total of 82 participants (42 females, mean age  $19.61 \pm 2.01$  years) for the  
132 final analyses. Each participant provided written informed consent for the study  
133 protocol approved by the ethical committee of the University of Electronic Science  
134 and Technology of China. The study was pre-registered as a clinical trial  
135 (ClinicalTrials.gov ID: NCT05468385).

### 136 **2.2. Procedure**

137 In a sham-controlled, single-blind, between-subject design, participants were  
138 randomly assigned to two groups, receiving real taVNS or sham stimulation  
139 respectively. Upon arrival, all subjects completed a number of validated psychometric  
140 questionnaires (details see in supplementary information) to exclude confounding  
141 effects of personality traits. In addition the Positive and Negative Affect  
142 Schedule(PANAS) was administered twice (before and immediately after the

143 experiment) to access mood changes (Watson *et al.*, 1988). Next, stimulation intensity  
144 was adjusted according to participants' subjective feelings (see section 2.3).  
145 Participants were then asked to rest for 5 minutes after familiarizing themselves with  
146 the emotional Go/No-Go tasks. Subsequently, resting-state brain activity was  
147 recorded using fNIRS while participants were instructed to relax and fixate on a white  
148 cross centered on the black screen during 15-minute period of stimulation (not  
149 reported here). Finally, following another 15 minutes' stimulation, participants were  
150 asked to complete the emotional Go/No-Go task (see section 2.4). At the end of the  
151 experiment, subjects were asked to report side effects of stimulation including  
152 headache, nausea, skin irritation under the electrode, relaxed, vigilant, unpleasant  
153 feelings, dizziness, neck pain, muscle contractions in the neck, and stinging sensation  
154 in the ear on a seven-point Likert scale (1: not at all, to 7: very much). An illustration  
155 of the procedure is presented in **Fig.1A**.

### 156 **2.3. Transcutaneous auricular vagus nerve stimulation**

157 In line with our previous study (Zhu *et al.*, 2022a), taVNS was implemented via a  
158 modified transcutaneous electrical acupoint stimulation device with an ear-clip  
159 electrode being attached to the left tragus for vagal stimulation in the taVNS group  
160 and to the left earlobe for sham stimulation in the control group. Electrical pulses  
161 (width, 500  $\mu$ s; frequency, 25 Hz) were delivered for 30 s, alternated by a 30 s pause  
162 for a total duration of 30 minutes (i.e., two stimulation periods with each lasting 15  
163 minutes). The auricular branch of vagus nerve (VN) is related to touch sensation,  
164 stimulation intensity was therefore individually calibrated to a level above the  
165 detection threshold but not generating any discomfort feeling to ensure VN activation  
166 (Ellrich, 2011). During the calibration procedure, participants received increasing and  
167 decreasing series of stimulation trials, and reported their subjective sensation of the  
168 stimulation on a 7-point Likert scale (1: feeling nothing, to 7: painful). The increasing  
169 series of trials started from 0 mA and elevated in steps of 0.1 mA until participants  
170 reported a "painful" sensation of 7. On the other hand, in decreasing series of trials,  
171 the "painful" intensity was repeated and then reduced in steps of 0.1 mA until a

172 subjective sensation of “feeling nothing” was experienced. This procedure was  
173 performed twice and the final stimulation intensity for each participant was calculated  
174 based on the average of four intensity values (i.e., two from increasing and two from  
175 decreasing trials) that were rated as 5 (i.e., obvious “tingling” sensation but not  
176 painful). The average stimulation intensity is 0.77 mA (0.3-1.2 mA) for the taVNS  
177 group, and is 0.94 mA (0.6-1.4 mA) for the sham-controlled group.

## 178 **2.4. Emotional Go/No-Go task**

179 The present study adopted an emotional face Go/No-Go task (see **Fig. 1A**). Each trial  
180 consisted of a white fixation cross ( $1250 \pm 250$  ms) on a black background and a  
181 random presentation of emotional faces (i.e., angry, happy and neutral) for 500 ms in  
182 the center of a 24-inch monitor at a resolution of 1024×768 pixels (60Hz) using  
183 E-prime 3.0 (Psychology Software Tools, Inc). Participants were required to respond  
184 to neutral faces as “Go” stimuli by pressing the button as fast as possible (i.e., before  
185 next trial) but to withhold responses when angry or happy faces as “No-Go” stimuli  
186 were presented. All 96 face images (48 neutral, 24 angry and 24 happy) were  
187 grayscale images with equivalent size and cumulative brightness, which were selected  
188 from the Chinese facial affective picture system (Gong *et al.*, 2011). This task  
189 consisted of 144 “Go” trials (each neutral face was presented 3 times) and 48 “No-Go”  
190 trials (each angry or happy face was presented once).

## 191 **2.5. Measurements**

### 192 **2.5.1 Behavioral performance and computational modeling of inhibitory ability**

193 To evaluate the effects of taVNS on response inhibition, behavioral performance  
194 including reaction time in Go trials (RT\_Go) and accuracy of No-Go trials  
195 (ACC\_No-Go) were measured. We also explored inhibitory ability using Hierarchical  
196 Bayesian estimation of the Drift Diffusion Model (HDDM, implemented in Python  
197 3.8 (Wiecki *et al.*, 2013)). The HDDM was fit to trial-by-trial measures of response  
198 type (i.e., “Go” vs. “No-Go”) and reaction times, and four parameters including drift  
199 rate ( $v$ , the rate of information accumulation toward the correct choice), starting point  
200 ( $z$ , a response bias for “Go” response or “No-Go” response), boundary separation ( $a$ ,

201 how much information is required to make a decision (i.e. the separation between the  
202 upper and lower boundary), and non-decision time ( $T_{er}$ , which reflects aspects of  
203 processing unrelated to decision making and represents sensory encoding and motor  
204 execution) were estimated across taVNS and sham-controlled groups respectively. For  
205 details of model framework **see Fig. 1B**, model estimation and model simulation see  
206 in Supplementary information.


### 207 **2.5.2 fNIRS data collection and neural measurements**

208 During the emotional Go/No-Go task, a NIRSport2 system (NIRx Medical  
209 Technologies LLC, Berlin, Germany) was utilized to measure the hemodynamic  
210 activity of each participant at a sampling frequency of 6.78 Hz. Thirty channels (12  
211 sources and 11 detectors) were placed bilaterally over the prefrontal cortex (**Fig. 1C**)  
212 based on fNIRS Optodes' location decider toolbox (fOLD v2.2) (Zimeo Morais *et al.*,  
213 2018). Notably, these regions are highly related to emotional inhibitory control based  
214 on previous studies (Munakata *et al.*, 2011; Zhuang *et al.*, 2021), including  
215 orbitofrontal cortex (OFC), inferior frontal gyrus (IFG), medial prefrontal cortex  
216 (mPFC), and dorsolateral prefrontal cortex (dlPFC). Each source-detector pair defined  
217 a single measurement channel with a distance of 3.0 cm and placement of fNIRS  
218 optodes was according to the 10-10 International System. Hair was manually parted  
219 under the optodes to improve signal detection.


220




### A Procedure timeline



### B Drift Diffusion Model framework



### C Overview of dFC analysis



221

222

223 **Fig. 1** Schematic illustration of experimental protocol and data analysis. A, Procedure

224 timeline. B, Drift Diffusion Model framework. C, Overview of dynamic functional

225 connectivity (dFC) analysis.

226

227

## 228 **2.6. Data analyses**

### 229 **2.6.1 Self-reported measures**

230 To exclude the potential confounding effects of self-reported mood and personality  
231 traits, independent  $t$  tests were performed separately with treatment (taVNS vs. sham)  
232 as the between group variable. Independent  $t$  tests for the side effect ratings between  
233 taVNS and sham stimulation group were also performed.

### 234 **2.6.2 Behavioral performance and computational model indices analyses**

235 Firstly, independent  $t$  tests were used to compare taVNS and sham groups for  
236 model-free indices (i.e., RT\_Go, and ACC\_No-Go) and HDDM-based indices ( $a$ ,  $v$ ,  $z$ ,  
237 and  $Ter$ ). Pearson correlation analyses were performed to investigate the relationship  
238 between the accuracy of No-Go and model-based indices. Finally, we further  
239 conducted a mediation analysis to investigate whether the drift rate for Go stimuli  
240 mediated the effect of taVNS on response inhibition performance by means of a  
241 bootstrapping method.

### 242 **2.6.3 Functional NIRs data analyses**

243 The fNIRS data were preprocessed and converted to time series of oxyhemoglobin  
244 (HbO) for each channel using NIRS-KIT (Hou *et al.*, 2021) (Supplementary Methods:  
245 fNIRS data preprocessing). Given HbO is a more sensitive indicator of  
246 task-associated changes relative to deoxyhemoglobin (HbR) (Ferrari and Quaresima,  
247 2012), we only focused on HbO in the further analyses.

#### 248 **2.6.3.1 Generalized linear model analyses**

249 The contrasts between “No-Go” and “Go” trials (i.e., angry vs. neutral, and happy vs.  
250 neutral) within 7 ROIs (i.e., left & right OFC, left & right IFG, left & right dlPFC and  
251 mPFC) were measured at the individual-level using generalized linear model (GLM)  
252 approach (see Supplementary information). The data were then subjected to a  
253 group-level analysis by means of repeated-measures ANOVA with ROI and emotion  
254 as two within-subject factors, and treatment as a between-subject factor. Bonferroni  
255 correction was applied to post hoc comparison tests.

#### 256 **2.6.3.2 fNIRS-Based dynamic functional connectivity analyses**

257 Dynamic functional connectivity was constructed using a sliding-window correlation  
258 analysis, and k-means clustering was applied to generate the key brain connectivity  
259 states under taVNS and sham conditions, respectively (Tang *et al.*, 2021; Lu *et al.*,  
260 2023). Firstly, dynamic functional connectivity analysis using the sliding window  
261 method (window length: 252 data points, ~37.1s) was conducted based on time series  
262 of HbO data from a total of 30 channels per participant to investigate the transient  
263 functional coupling (FC) within prefrontal regions during the whole emotional  
264 Go/No-Go task. Further, we adopted k-means algorithm (L1 distance) to cluster all  
265 the calculated functional connectomes to estimate the reoccurring functional states  
266 (patterns) of task-based time-varying oscillations of HbO signal (details see  
267 Supplementary information). Finally, treatment groups were compared on FCs within  
268 each state using independent *t* tests with permutations for multiple comparisons  
269 (Nichols and Holmes, 2002; Camargo *et al.*, 2008). We further employed Pearson  
270 correlation with permutation tests (10000 permutations) to identify which prefrontal  
271 FCs was highly contributed to inhibition performance. Mediation analysis was  
272 performed to investigate whether these FCs mediated taVNS effects on inhibition  
273 ability. Overview of the analyses was illustrated in **Fig. 1C**.

## 274 **3. Results**


### 275 **3.1. Comparable participant characteristics in the treatment groups**

276 Participant characteristics are summarized in **Table 1**, the two treatment groups did  
277 not differ significantly in terms of age ( $p = 0.744$ ), gender ( $p = 0.659$ ), mood ( $ps > 0.15$ ),  
278 personality traits ( $ps > 0.17$ ), and subjective ratings for the stimulation adverse effects  
279 ( $ps > 0.13$ ).

### 280 **3.2. Effects of taVNS on response inhibition performance and its 281 computational mechanism**

282 Repeated measures ANOVA was conducted for ACC\_No-Go with emotion (i.e.,  
283 angry and happy) as a within-subject factor and treatment as group factor,  
284 independent *t* tests were performed to investigate taVNS effects on RT\_Go and  
285 HDDM-based indices (a, v, z, and Ter) respectively. Results showed no significant


286 interaction between emotion and treatment ( $F_{[1, 80]} = 5.12, p = 0.0256$ ) but a significant  
287 treatment effect on ACC\_No-Go ( $F_{[1, 80]} = 5.18, p = 0.026$ , partial  $\eta^2 = 0.061$ ),  
288 indicating an increased accuracy of No-Go trials following taVNS compared to sham  
289 treatment. The ANOVA results did not change with the stimulation intensity as a  
290 covariate factor. No change in reaction time for correct Go trials was found under  
291 treatment ( $t_{[80]} = 0.38, p = 0.703$ , **Fig. 2A**). Additionally, drift rate for Go trials  
292 decreased in the taVNS relative to the sham group ( $t_{[80]} = -2.29, p = 0.025$ , Cohen's  $d$   
293  $= 0.506$ , **Fig. 2B**) and there were no group differences in the rest of the HDDM  
294 indices (a:  $t_{[80]} = -0.50, p = 0.621$ ; v\_nogo:  $t_{[80]} = -0.60, p = 0.552$ ; Ter:  $t_{[80]} = 0.50, p$   
295  $= 0.618$ ; z:  $t_{[80]} = 1.26, p = 0.212$ , each individual plot of observed vs. simulated  
296 responses across taVNS and sham is shown in Supplementary information **Figure**  
297 **S1-S18**), and an example of the HDDM simulation results are presented in **Fig. 3**.  
298 Mediation results showed that taVNS decreased drift rate for Go stimuli (path  $a =$   
299  $0.57, p = 0.025$ ) and drift rate was negatively associated with accuracy of No-Go trials  
300 (path  $b = -2.95, p = 0.014$ ). Importantly, the indirect effect (path  $a \times b$ ) reached  
301 significance, suggesting drift rate for Go stimuli mediated taVNS effects on  
302 increasing inhibition performance (indirect effect  $= -1.68, 95\% \text{ CI} = [-3.98, -0.10]$ ,



303 bootstrap = 5000, see **Fig. 2C**).

304

305 **Fig. 2** taVNS effects on behavioral index. A, Accuracy of No-Go response (mean  $\pm$   
306 SEM) under two treatment groups. B, Computed Hierarchical Bayesian estimation of  
307 the Drift Diffusion Model (HDDM) parameter differences between treatment groups.  
308 C, Drift rate of Go response mediated taVNS effects on the accuracy of No-Go  
309 response. \*  $p < .05$ . \*\*  $p < .01$ , \*\*\*  $p < .001$ , ns: no significant difference.



310

311 **Fig. 3** HDDM simulation results. Representative plot of observed vs. simulated  
312 responses (i.e., accuracy and reaction times) across taVNS and sham condition.  
313 Columns 1 and 3 represent probability densities. Columns 2 and 4 represent  
314 percentage of correct responses in each reaction time quantile. Obs = observed. Sim =  
315 simulated. Corr = correct. Incorr = incorrect.

316

### 317 3.3. taVNS effects on brain activity during response inhibition

318 A three-way repeated-measures ANOVA was performed on brain activity with ROI  
319 and emotion (i.e., angry vs. neutral, happy vs. neutral) as two within-subject factors,  
320 and treatment as a between-subject factor. Results revealed there was a significant  
321 three-way interaction effect ( $F_{[6, 480]} = 2.69$ ,  $p = 0.033$ , partial  $\eta^2 = 0.033$ ), suggesting  
322 that taVNS increased the activity of both right IFG ( $p = 0.015$ , Cohen's  $d = 0.547$ ) and  
323 left IFG ( $p = 0.044$ , Cohen's  $d = 0.453$ , Bonferroni correction) in response to angry  
324 No-Go faces (**Fig. 4A**). In addition, the results did not change if we averaged the left  
325 and right regions (i.e. 4 ROIs, IFG, mPFC, dlPFC and OFC,  $F_{[3, 240]} = 3.271$ ,  $p =$   
326  $0.031$ , partial  $\eta^2 = 0.039$ ).

### 327 **3.4. taVNS effects on task-related prefrontal functional couplings**

328 Four states were determined by k-means clustering and independent permutation *t* test  
329 (10000 permutations) results showed that taVNS increased both between FCs  
330 including dlPFC- IFG/OFC/mPFC, OFC-IFG/mPFC couplings and within FCs among  
331 these four regions in state 1, and increased IFG-mPFC FCs in state 2. Notably, taVNS  
332 increased FCs including IFG-OFC/dlPFC, dlPFC- mPFC/OFC and FC within dlPFC  
333 while decreasing specific FCs including mPFC- dlPFC/OFC, OFC-dlPFC, and FC  
334 within OFC in state 3. In state 4, taVNS increased FCs including IFG  
335 -OFC/dlPFC/mPFC, dlPFC-OFC/mPFC, and FCs within dlPFC and mPFC while  
336 decreasing specific FCs including OFC-dlPFC/mPFC (all  $ps < 0.05$ , **Fig. 4B** and more  
337 details see Supplementary information Table S1- Table S4).


338 Mediation analyses indicated that taVNS increased FC between IFG and OFC in  
339 state 4 (path  $a = -0.15$ ,  $p < 0.001$ ) and this FC was positively correlated with  
340 increased ACC\_No-Go (path  $b = 21.35$ ,  $p = 0.002$ ). Notably, the indirect effect was  
341 significant showing that the coupling between IFG and OFC in state 4 mediated  
342 taVNS effects on increasing responses inhibition performance (indirect effect =  $-3.26$ ,  
343 95% CI =  $[-6.92, -0.61]$ , bootstrap = 5000, see **Fig. 4C**).

### 344 **3.5. Computational modeling of taVNS effects on inhibition** 345 **performance**

346 To further determine the underlying neurocomputational mechanism of  
347 taVNS-induced enhanced response inhibition, a parallel mediation analysis was  
348 conducted with drift rate for Go stimuli and FC between IFG and OFC in state 4  
349 serving as mediating variables. The results revealed that the total effect of treatment  
350 on accuracy of No-Go trials was significant (path  $c = -6.15$ ,  $p = 0.026$ ) while the  
351 direct effect was not (path  $c' = -1.78$ ,  $p = 0.518$ ). Specifically, the impact of taVNS on  
352 inhibition performance was mediated by drift rate for Go stimuli (indirect effect 1 =  
353  $-1.42$ , 95% CI =  $[-3.51, -0.02]$ ) and FC between IFG and OFC in state 4 (indirect  
354 effect 2 =  $-2.95$ , 95% CI =  $[-6.53, -0.32]$ ). A further comparison regarding the size of  
355 the mediation effect (Indirect 1 – Indirect 2 =  $1.53$ , 95% CI =  $[-1.67, 5.24]$ , bootstrap



356 = 5000) showed that decreased drift rate for Go stimuli and enhanced FC between  
 357 IFG and OFC equally mediated the effect of taVNS on response inhibition (see **Fig.**  
 358 **4D**).



359

360 **Fig. 4** fNIRS results. A, HbO differences of bilateral IFG for inhibition on angry and  
 361 happy faces under taVNS and sham treatment. B, Different effects of treatment on  
 362 FCs in determined State 1, State 2, State 3, and State 4 respectively, red line/box:  
 363 taVNS > sham; blue line/box: taVNS < sham. C, Mediation analysis between  
 364 treatment, FC between IFG and OFC, and accuracy of No-Go response. D, Parallel

365 mediation analysis between treatment, FC between IFG and OFC, drift rate for Go  
366 stimuli and accuracy of No-Go response. FC-functional connectivity; IFG-Inferior  
367 frontal gyrus; OFC- Orbitofrontal cortex. \*  $p < .05$ , \*\*  $p < .01$ , \*\*\*  $p < .001$ .

368



## 369 **4. Discussion**

370 In the current study, we explored the potential of taVNS as a non-invasive  
371 neuromodulation technique to enhance inhibitory control. In line with our hypothesis,  
372 taVNS improved inhibition accuracy and increased the activation of bilateral IFG for  
373 inhibition during presentation of angry expression faces. During the entire emotional  
374 Go/No-Go task, four states were determined by k-means clustering and taVNS  
375 modulated the functional coupling within four key regions including OFC, dlPFC,  
376 mPFC and IFG regions in the respective states. Most importantly, mediation results  
377 suggested that the decreased rate of information accumulation for correct Go response  
378 calculated by HDDM computational modeling combined with increased IFG-OFC  
379 functional coupling equally mediated the taVNS-induced enhancement of inhibition.

380 In line with preliminary evidence (Beste *et al.*, 2016; Keute *et al.*, 2020; Pihlaja  
381 *et al.*, 2020), our study found that taVNS increased accuracy of correct No-Go  
382 responses (i.e., ACC\_No-Go) compared to sham stimulation, indicating a beneficial  
383 effect of taVNS on improving inhibitory control ability (Wright *et al.*, 2014).  
384 Furthermore, the computational model assumes that the individual's decision-making  
385 process after encoding the corresponding stimulus (such as sensory information  
386 encoding, etc.) begins from a starting point and accumulates information along the  
387 direction of two decision options until reaching the response boundary (Gomez *et al.*,  
388 2007; Ratcliff *et al.*, 2018). The HDDM findings consistently showed that taVNS  
389 specifically decreased speed of information accumulation toward Go response (drift  
390 rate) in turn facilitating inhibitory control. These results suggest that taVNS may  
391 decelerate the top-down cognitive processing for Go responses during the present  
392 emotional Go/No-Go task, thereby breaking the pre-potent Go responses to improve  
393 response inhibition performance.

394 On the other hand, GLM results revealed increased activity in bilateral IFG,  
395 although stronger in the right side for angry expression faces, was found under active  
396 taVNS. It has been proposed that IFG, especially the right side, is a pivotal neural hub  
397 in regulating behavioral inhibition, and the activation of IFG was positively correlated

398 with inhibitory control ability (Rubia *et al.*, 2003; Aron *et al.*, 2007; Chevrier *et al.*,  
399 2007; Zhuang *et al.*, 2022). Considering that ADHD children show reduced activation  
400 in right IFG relative to normal controls during Go/No-Go task (Monden *et al.*, 2012).  
401 taVNS may be a promising approach as treatment for ADHD. Additionally, activation  
402 of the right IFG is also associated with anger processing (Nomura *et al.*, 2004; Taylor  
403 *et al.*, 2018; Iarrobino *et al.*, 2021; Sorella *et al.*, 2021). By contrast, there were no  
404 significant changes under inhibition for happy expression faces following taVNS  
405 which may due to different pathways involved in inhibition of angry and happy  
406 stimuli. For example, differences in subcortical regions (i.e. striatum) activation have  
407 been found in positive and negative inhibition responses (Zhuang *et al.*, 2021),  
408 although these regions cannot be detected using fNIRS. Thus overall, the  
409 enhancement of IFG activation suggests a critical role of IFG in modulating the effect  
410 of taVNS on emotional response inhibition, especially in the context of negative  
411 angry expression stimuli.

412 Notably, dynamic functional connectivity analyses also suggested that functional  
413 couplings (FCs) within prefrontal cortex including IFG, OFC, dlPFC and mPFC  
414 during the whole emotional inhibition task were significantly modulated by taVNS.  
415 This approach helps us quantify the experimental paradigm-based variations of brain  
416 functional networks affected by taVNS regardless of conditions (Tang *et al.*, 2021; Lu  
417 *et al.*, 2023). Among these couplings, taVNS significantly strengthened dlPFC-  
418 mPFC/ IFG/OFC/ dlPFC and OFC-IFG links in States1, 3 and 4, suggesting that such  
419 dlPFC- and OFC- related functional couplings played primary role in taVNS effects  
420 on emotional inhibitory processes. Most importantly, the positive impact of taVNS on  
421 inhibition performance was mediated by the increased functional coupling between  
422 IFG and OFC. Findings indicate that IFG-OFC coupling is involved in emotional  
423 inhibitory control. For example, individuals with higher strength IFG -OFC coupling  
424 were more flexible in regulating cognitive control and emotional processing (Shi *et al.*,  
425 2019) and the OFC plays a key role in serving inhibitory control in emotional context  
426 (Robertson *et al.*, 2015; Stalnaker *et al.*, 2015; Zhuang *et al.*, 2021). Taken together,

427 the increased FC between IFG and OFC might be the neural basis of enhanced  
428 inhibitory control for emotional faces under taVNS.

429 To further elucidate the neurocomputational mechanisms underlying the taVNS  
430 effect on emotional inhibitory control, a parallel mediation model was used and  
431 revealed that the positive effect of taVNS on inhibition performance was mediated by  
432 decreased drift rate for Go response in conjunction with increased FC between IFG  
433 and OFC. These results indicated that taVNS may improve response inhibition  
434 performance via its modulation of control ability for making Go responses more  
435 precise and enhancing FC within the prefrontal inhibitory control network.

436 Some limitations of the current study should be acknowledged. Firstly, some  
437 evidence from both animal and clinical studies proposed that taVNS would improve  
438 inhibitory control ability via modulating the LC-NE system (Burger *et al.*, 2020;  
439 Colzato and Beste, 2020). Although prefrontal cortex circuits have been widely  
440 regarded as the center network of inhibition control ability (Goldstein *et al.*, 2007)  
441 and LC-NE system could modulate the functional connectivity within the prefrontal  
442 inhibitory control network (Passamonti *et al.*, 2018; Tomassini *et al.*, 2022), given  
443 neural activities from subcortical regions cannot be detected through fNIRS technique,  
444 subcortical networks, such as basal ganglia, hypothalamus could be further  
445 investigated under taVNS, for example using deep brain stimulation techniques. Pupil  
446 diameter is also related to NE-LC system (Burger *et al.*, 2020) although in our  
447 previous study we did not find any significant effects of taVNS on this (Zhu *et al.*,  
448 2022a). In addition, the current study only recruited healthy subjects and more clinical  
449 samples, especially individuals with deficits in inhibition control (e.g., ADHD, PTSD,  
450 addiction disorders) should be included to confirm and validate the positive effects of  
451 taVNS and their therapeutic potential.

452 In conclusion, the present study demonstrated a beneficial effect of taVNS on  
453 improving inhibitory control and further revealed the neurocomputational  
454 mechanisms underlying this effect in healthy individuals, suggesting a therapeutic  
455 potential of taVNS as a promising neuromodulation technique in the intervention of

456 psychiatric disorders characterized inhibitory control deficits, such as attention deficit  
457 hyperactivity disorder, substance abuse disorder, and post-traumatic stress disorder.  
458

## 459 **Acknowledgments**

460 This work was supported by Natural Science Foundation of Sichuan Province [grant  
461 number 2022NSFSC1375 - WHZ], Fundamental Research Funds for the Central  
462 Universities, UESTC [grant number ZYGX2020J027 - WHZ], National Natural  
463 Science Foundation of China (NSFC) [grant number 31530032 - KMK], the Special  
464 Fund for Basic Scientific Research of Central Colleges (grant number  
465 ZYGX2021J036 - KMK) and Key Scientific and Technological projects of  
466 Guangdong Province [grant number 2018B030335001 - KMK].

467

## 468 **Disclosure**

469 The authors report no conflicts of interest.

470

## 471 **Availability of Data and Materials**

472 Data in the present study can be made available upon request to the primary contact  
473 author, and code will be shared upon publication through a GitHub repository.

474

475

476

477

478

479

480

481

## 482 **References**

- 483 **Aron AR, Behrens TE, Smith S, Frank MJ, Poldrack RA** (2007) Triangulating a  
484 Cognitive Control Network Using Diffusion-Weighted Magnetic Resonance Imaging  
485 (MRI) and Functional MRI. Society for Neuroscience *Journal of Neuroscience* **27**,  
486 3743–3752.
- 487 **Beste C, Steenbergen L, Sellaro R, Grigoriadou S, Zhang R, Chmielewski W,**  
488 **Stock A-K, Colzato L** (2016) Effects of Concomitant Stimulation of the GABAergic  
489 and Norepinephrine System on Inhibitory Control – A Study Using Transcutaneous  
490 Vagus Nerve Stimulation. *Brain Stimulation* **9**, 811–818.
- 491 **Borges U, Knops L, Laborde S, Klatt S, Raab M** (2020) Transcutaneous Vagus  
492 Nerve Stimulation May Enhance Only Specific Aspects of the Core Executive  
493 Functions. A Randomized Crossover Trial. *Frontiers in Neuroscience* **14**.
- 494 **Burger AM, D’Agostini M, Verkuil B, Diest IV** (2020) Moving beyond belief: A  
495 narrative review of potential biomarkers for transcutaneous vagus nerve stimulation.  
496 *Psychophysiology* **57**, e13571.
- 497 **Camargo A, Azuaje F, Wang H, Zheng H** (2008) Permutation – based statistical  
498 tests for multiple hypotheses. *Source Code for Biology and Medicine* **3**, 15.
- 499 **Capone F, Assenza G, Di Pino G, Musumeci G, Ranieri F, Florio L, Barbato C,**  
500 **Di Lazzaro V** (2015) The effect of transcutaneous vagus nerve stimulation on cortical  
501 excitability. *Journal of Neural Transmission* **122**, 679–685.
- 502 **Catarino A, Küpper CS, Werner-Seidler A, Dalgleish T, Anderson MC** (2015)  
503 Failing to Forget: Inhibitory-Control Deficits Compromise Memory Suppression in  
504 Posttraumatic Stress Disorder. SAGE Publications Inc *Psychological Science* **26**,  
505 604–616.
- 506 **Chamberlain SR, Campo N del, Dowson J, Müller U, Clark L, Robbins TW,**  
507 **Sahakian BJ** (2007) Atomoxetine Improved Response Inhibition in Adults with  
508 Attention Deficit/Hyperactivity Disorder. Elsevier *Biological Psychiatry* **62**, 977–984.
- 509 **Chamberlain SR, Hampshire A, Müller U, Rubia K, Campo N del, Craig K,**  
510 **Regenthal R, Suckling J, Roiser JP, Grant JE, Bullmore ET, Robbins TW,**  
511 **Sahakian BJ** (2009) Atomoxetine Modulates Right Inferior Frontal Activation  
512 During Inhibitory Control: A Pharmacological Functional Magnetic Resonance  
513 Imaging Study. Elsevier *Biological Psychiatry* **65**, 550–555.
- 514 **Chevrier AD, Noseworthy MD, Schachar R** (2007) Dissociation of response  
515 inhibition and performance monitoring in the stop signal task using event-related  
516 fMRI. *Human Brain Mapping* **28**, 1347–1358.

- 517 **Colzato L, Beste C** (2020) A literature review on the neurophysiological  
518 underpinnings and cognitive effects of transcutaneous vagus nerve stimulation:  
519 challenges and future directions. *American Physiological Society Journal of*  
520 *Neurophysiology* **123**, 1739–1755.
- 521 **Diamond A** (2013) Executive Functions. *Annual review of psychology* **64**, 135–168.
- 522 **Ellrich J** (2011) Transcutaneous vagus nerve stimulation. *European Neurological*  
523 *Review* **6**, 254–256.
- 524 **Ferrari M, Quaresima V** (2012) A brief review on the history of human functional  
525 near-infrared spectroscopy (fNIRS) development and fields of application.  
526 *NeuroImage* **63**, 921–935.
- 527 **Fischer R, Ventura-Bort C, Hamm A, Weymar M** (2018) Transcutaneous vagus  
528 nerve stimulation (tVNS) enhances conflict-triggered adjustment of cognitive control.  
529 *Cognitive, Affective, & Behavioral Neuroscience* **18**, 680–693.
- 530 **Frangos E, Ellrich J, Komisaruk BR** (2015) Non-invasive Access to the Vagus  
531 Nerve Central Projections via Electrical Stimulation of the External Ear: fMRI  
532 Evidence in Humans. *Brain Stimulation* **8**, 624–636.
- 533 **de Gee JW, Tsetsos K, Schwabe L, Urai AE, McCormick D, McGinley MJ,**  
534 **Donner TH** (2020) Pupil-linked phasic arousal predicts a reduction of choice bias  
535 across species and decision domains. ed. J. I. Gold, M. Grüschow and R. B. Ebitz  
536 eLife Sciences Publications, Ltd *eLife* **9**, e54014.
- 537 **Goldstein M, Brendel G, Tuescher O, Pan H, Epstein J, Beutel M, Yang Y,**  
538 **Thomas K, Levy K, Silverman M, Clarkin J, Posner M, Kernberg O, Stern E,**  
539 **Silbersweig D** (2007) Neural substrates of the interaction of emotional stimulus  
540 processing and motor inhibitory control: An emotional linguistic go/no-go fMRI study.  
541 *NeuroImage* **36**, 1026–1040.
- 542 **Gomez P, Ratcliff R, Perea M** (2007) A model of the go/no-go task. US: American  
543 Psychological Association *Journal of Experimental Psychology: General* **136**,  
544 389–413.
- 545 **Gong X, Huang Y-X, Wang Y, Luo Y-J** (2011) Revision of the Chinese Facial  
546 Affective Picture System. China: Chinese Mental Health *Chinese Mental Health*  
547 *Journal* **25**, 40–46.
- 548 **Gorka AX, Philips RT, Torrisi S, Claudino L, Foray K, Grillon C, Ernst M** (2022)  
549 The Posterior Cingulate Cortex Reflects the Impact of Anxiety on Drift Rates During  
550 Cognitive Processing. *Biological Psychiatry: Cognitive Neuroscience and*  
551 *Neuroimaging*.

- 552 **Hermans L, Leunissen I, Pauwels L, Cuypers K, Peeters R, Puts NAJ, Edden**  
553 **RAE, Swinnen SP** (2018) Brain GABA Levels Are Associated with Inhibitory  
554 Control Deficits in Older Adults. Society for Neuroscience *Journal of Neuroscience*  
555 **38**, 7844–7851.
- 556 **Hildebrandt MK, Dieterich R, Endrass T** (2021) Neural correlates of inhibitory  
557 control in relation to the degree of substance use and substance-related problems - A  
558 systematic review and perspective. *Neuroscience and Biobehavioral Reviews* **128**,  
559 1–11.
- 560 **Hou X, Zhang Z, Zhao C, Duan L, Gong Y, Li Z, Zhu C** (2021) NIRS-KIT: a  
561 MATLAB toolbox for both resting-state and task fNIRS data analysis. *SPIE*  
562 *Neurophotonics* **8**, 010802.
- 563 **Huang-Pollock C, Ratcliff R, McKoon G, Shapiro Z, Weigard A, Galloway-Long**  
564 **H** (2017) Using the Diffusion Model to Explain Cognitive Deficits in Attention  
565 Deficit Hyperactivity Disorder. *Journal of Abnormal Child Psychology* **45**, 57–68.
- 566 **Iarrobino I, Bongiardina A, Dal Monte O, Sarasso P, Ronga I, Neppi-Modona M,**  
567 **Actis-Grosso R, Salatino A, Ricci R** (2021) Right and left inferior frontal opercula  
568 are involved in discriminating angry and sad facial expressions. *Brain Stimulation* **14**,  
569 607–615.
- 570 **Jasinska AJ, Yasuda M, Burant CF, Gregor N, Khatri S, Sweet M, Falk EB**  
571 (2012) Impulsivity and inhibitory control deficits are associated with unhealthy eating  
572 in young adults. *Appetite* **59**, 738–747.
- 573 **Keute M, Barth D, Liebrand M, Heinze H-J, Kraemer U, Zaehle T** (2020) Effects  
574 of Transcutaneous Vagus Nerve Stimulation (tVNS) on Conflict-Related Behavioral  
575 Performance and Frontal Midline Theta Activity. *Journal of Cognitive Enhancement*  
576 **4**, 121–130.
- 577 **Li J, Yang X, Zhou F, Liu C, Wei Z, Xin F, Daumann B, Daumann J, Kendrick**  
578 **KM, Becker B** (2020) Modafinil enhances cognitive, but not emotional conflict  
579 processing via enhanced inferior frontal gyrus activation and its communication with  
580 the dorsomedial prefrontal cortex. Nature Publishing Group  
581 *Neuropsychopharmacology* **6 45**, 1026–1033.
- 582 **Lu J, Zhang X, Wang Y, Cheng Y, Shu Z, Wang J, Zhu Z, Liu P, Yu Y, Wu J,**  
583 **Han J, Yu N** (2023) An fNIRS-Based Dynamic Functional Connectivity Analysis  
584 Method to Signify Functional Neurodegeneration of Parkinson’s Disease. *IEEE*  
585 *Transactions on Neural Systems and Rehabilitation Engineering* **31**, 1199–1207.
- 586 **Monden Y, Dan H, Nagashima M, Dan I, Tsuzuki D, Kyutoku Y, Gunji Y,**  
587 **Yamagata T, Watanabe E, Momoi MY** (2012) Right prefrontal activation as a



- 588 neuro-functional biomarker for monitoring acute effects of methylphenidate in ADHD  
589 children: An fNIRS study. *NeuroImage: Clinical* **1**, 131–140.
- 590 **Munakata Y, Herd SA, Chatham CH, Depue BE, Banich MT, O’Reilly RC** (2011)  
591 A unified framework for inhibitory control. Elsevier *Trends in Cognitive Sciences* **15**,  
592 453–459.
- 593 **Murley AG, Rouse MA, Jones PS, Ye R, Hezemans FH, O’Callaghan C, Frangou**  
594 **P, Kourtzi Z, Rua C, Carpenter TA, Rodgers CT, Rowe JB** (2020) GABA and  
595 glutamate deficits from frontotemporal lobar degeneration are associated with  
596 disinhibition. *Brain* **143**, 3449–3462.
- 597 **Nichols TE, Holmes AP** (2002) Nonparametric permutation tests for functional  
598 neuroimaging: A primer with examples. *Human Brain Mapping* **15**, 1–25.
- 599 **Nomura M, Ohira H, Haneda K, Iidaka T, Sadato N, Okada T, Yonekura Y**  
600 (2004) Functional association of the amygdala and ventral prefrontal cortex during  
601 cognitive evaluation of facial expressions primed by masked angry faces: an  
602 event-related fMRI study. *NeuroImage* **21**, 352–363.
- 603 **O’Callaghan C, Hezemans FH, Ye R, Rua C, Jones PS, Murley AG, Holland N,**  
604 **Regenthal R, Tsvetanov KA, Wolpe N, Barker RA, Williams-Gray CH, Robbins**  
605 **TW, Passamonti L, Rowe JB** (2021) Locus coeruleus integrity and the effect of  
606 atomoxetine on response inhibition in Parkinson’s disease. *Brain* **144**, 2513–2526.
- 607 **Passamonti L, Lansdall C, Rowe J** (2018) The neuroanatomical and neurochemical  
608 basis of apathy and impulsivity in frontotemporal lobar degeneration. *Current*  
609 *Opinion in Behavioral Sciences* **22**, 14–20.
- 610 **Pihlaja M, Failla L, Peräkylä J, Hartikainen KM** (2020) Reduced Frontal  
611 Nogo-N2 With Uncompromised Response Inhibition During Transcutaneous Vagus  
612 Nerve Stimulation—More Efficient Cognitive Control? *Frontiers in Human*  
613 *Neuroscience* **14**.
- 614 **Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA** (2007) The  
615 Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis.  
616 American Psychiatric Publishing *American Journal of Psychiatry* **164**, 942–948.
- 617 **Ratcliff R, Huang-Pollock C, McKoon G** (2018) Modeling individual differences in  
618 the go/no-go task with a diffusion model. US: Educational Publishing Foundation  
619 *Decision* **5**, 42–62.
- 620 **Robertson CL, Ishibashi K, Mandelkern MA, Brown AK, Ghahremani DG,**  
621 **Sabb F, Bilder R, Cannon T, Borg J, London ED** (2015) Striatal D1- and D2-type  
622 Dopamine Receptors Are Linked to Motor Response Inhibition in Human Subjects.  
623 Society for Neuroscience *Journal of Neuroscience* **35**, 5990–5997.

- 624 **Rubia K, Smith AB, Brammer MJ, Taylor E** (2003) Right inferior prefrontal cortex  
625 mediates response inhibition while mesial prefrontal cortex is responsible for error  
626 detection. *NeuroImage* **20**, 351–358.
- 627 **Sakai J** (2022) Functional near-infrared spectroscopy reveals brain activity on the  
628 move. *Proceedings of the National Academy of Sciences Proceedings of the National*  
629 *Academy of Sciences* **119**, e2208729119.
- 630 **Shi L, Sun J, Wei D, Qiu J** (2019) Recover from the adversity: functional  
631 connectivity basis of psychological resilience. *Neuropsychologia* **122**, 20–27.
- 632 **Sorella S, Grecucci A, Piretti L, Job R** (2021) Do anger perception and the  
633 experience of anger share common neural mechanisms? Coordinate-based  
634 meta-analytic evidence of similar and different mechanisms from functional  
635 neuroimaging studies. *NeuroImage* **230**, 117777.
- 636 **Stalnaker TA, Cooch NK, Schoenbaum G** (2015) What the orbitofrontal cortex  
637 does not do. *Nature Publishing Group Nature Neuroscience* **5** **18**, 620–627.
- 638 **Tang TB, Chong JS, Kiguchi M, Funane T, Lu C-K** (2021) Detection of Emotional  
639 Sensitivity Using fNIRS Based Dynamic Functional Connectivity. *IEEE Transactions*  
640 *on Neural Systems and Rehabilitation Engineering* **29**, 894–904.
- 641 **Taylor MJ, Robertson A, Keller AE, Sato J, Urbain C, Pang EW** (2018)  
642 Inhibition in the face of emotion: Characterization of the spatial-temporal dynamics  
643 that facilitate automatic emotion regulation. *Human Brain Mapping* **39**, 2907–2916.
- 644 **Tomassini A, Hezemans FH, Ye R, Tsvetanov KA, Wolpe N, Rowe JB** (2022)  
645 Prefrontal Cortical Connectivity Mediates Locus Coeruleus Noradrenergic Regulation  
646 of Inhibitory Control in Older Adults. *Society for Neuroscience Journal of*  
647 *Neuroscience* **42**, 3484–3493.
- 648 **Watson D, Clark LA, Carey G** (1988) Positive and negative affectivity and their  
649 relation to anxiety and depressive disorders. US: American Psychological Association  
650 *Journal of Abnormal Psychology* **97**, 346–353.
- 651 **Weigard A, Soules M, Ferris B, Zucker RA, Sripada C, Heitzeg M** (2020)  
652 Cognitive Modeling Informs Interpretation of Go/No-Go Task-Related Neural  
653 Activations and Their Links to Externalizing Psychopathology. *Biological Psychiatry:*  
654 *Cognitive Neuroscience and Neuroimaging* **5**, 530–541.
- 655 **Wiecki T, Sofer I, Frank M** (2013) HDDM: Hierarchical Bayesian estimation of the  
656 Drift-Diffusion Model in Python. *Frontiers in Neuroinformatics* **7**.
- 657 **Wright L, Lipszyc J, Dupuis A, Thayapararajah SW, Schachar R** (2014)  
658 Response inhibition and psychopathology: A meta-analysis of go/no-go task

659 performance. US: American Psychological Association *Journal of Abnormal*  
660 *Psychology* **123**, 429–439.

661 **Yakunina N, Kim SS, Nam E-C** (2017) Optimization of Transcutaneous Vagus  
662 Nerve Stimulation Using Functional MRI. *Neuromodulation: Technology at the*  
663 *Neural Interface* **20**, 290–300.

664 **Zhang J, Rittman T, Nombela C, Fois A, Coyle-Gilchrist I, Barker RA, Hughes**  
665 **LE, Rowe JB** (2016) Different decision deficits impair response inhibition in  
666 progressive supranuclear palsy and Parkinson’s disease. *Brain* **139**, 161–173.

667 **Zhu S, Qing Y, Zhang Y, Zhang X, Ding F, Zhang R, Yao S, Kendrick KM,**  
668 **Zhao W** (2022a) Transcutaneous auricular vagus nerve stimulation increases  
669 eye-gaze on salient facial features and oxytocin release. *Psychophysiology* **59**,  
670 e14107.

671 **Zhu S, Zhang X, Zhou M, Kendrick KM, Zhao W** (2022b) Therapeutic  
672 applications of transcutaneous auricular vagus nerve stimulation with potential for  
673 application in neurodevelopmental or other pediatric disorders. *Frontiers in*  
674 *Endocrinology* **13**.

675 **Zhuang Q, Qiao L, Xu L, Yao S, Chen S, Zheng X, Li J, Fu M, Li K, Vatansever**  
676 **D, Ferraro S, Kendrick KM, Becker B** (2022) The right inferior frontal gyrus as  
677 pivotal node and effective regulator of the basal ganglia-thalamocortical response  
678 inhibition circuit. bioRxiv 2022.05.26.493546.

679 **Zhuang Q, Xu L, Zhou F, Yao S, Zheng X, Zhou X, Li J, Xu X, Fu M, Li K,**  
680 **Vatansever D, Kendrick KM, Becker B** (2021) Segregating domain-general from  
681 emotional context-specific inhibitory control systems - ventral striatum and  
682 orbitofrontal cortex serve as emotion-cognition integration hubs. *NeuroImage* **238**,  
683 118269.

684 **Zimeo Morais GA, Balardin JB, Sato JR** (2018) fNIRS Optodes’ Location Decider  
685 (fOLD): a toolbox for probe arrangement guided by brain regions-of-interest. Nature  
686 Publishing Group *Scientific Reports* **1 8**, 3341.

687

688

689

690 **Tables**

691 **Table 1.** Sample characteristics and self-reported measurements (mean  $\pm$  SEM).

	<b>taVNS (n=41)</b>	<b>Sham (n=41)</b>	<b>Statistics</b>	<b>P</b>
Gender	19 males	21 males	$\chi^2(1) = 0.20$	0.659
Age	19.68(0.31)	19.54(0.32)	$t(80) = 0.33$	0.744
<b>PANAS and SAI scores</b>				
<b>Pre-task</b>				
Positive scores	24.20(0.84)	24.44(1.01)	$t(80) = -0.19$	0.853
Negative scores	15.27(1.05)	13.41(0.75)	$t(80) = 1.44$	0.153
SAI scores	40.56(1.32)	41.34(1.40)	$t(80) = -0.41$	0.686
<b>Post-task</b>				
Positive scores	21.34(0.97)	20.85(1.01)	$t(80) = 0.35$	0.728
Negative scores	12.27(0.87)	11.71(0.57)	$t(80) = 0.54$	0.592
SAI scores	37.12(1.17)	38.05(1.44)	$t(80) = -0.50$	0.619
<b>Personality traits</b>				
TAI	41.76(1.17)	42.98(1.35)	$t(80) = -0.68$	0.497
BDI	8.27(1.03)	9.54(1.21)	$t(80) = -0.80$	0.426
ASQ	22.17(0.93)	21.20(0.74)	$t(80) = 0.82$	0.414
SIAS	59.05(2.19)	54.76(2.28)	$t(80) = 1.36$	0.178
BIS	14.34(0.42)	13.44(0.34)	$t(80) = 1.67$	0.098
BAS_Rewardresponsiveness	6.17(0.28)	5.93(0.25)	$t(80) = 0.65$	0.521
BAS_Drive	7.34(0.31)	7.76(0.34)	$t(80) = -0.90$	0.369
BAS_Funseeking	9.85(0.38)	9.88(0.38)	$t(80) = -0.05$	0.964
BIS_Attentional	15.12(0.60)	14.66(0.52)	$t(80) = 0.59$	0.559
BIS_Motor	20.41(0.55)	19.51(0.56)	$t(80) = 1.16$	0.250
BIS_Nonplanning	23.80(0.82)	22.5(0.76)	$t(80) = 0.77$	0.446
<b>Subjective ratings for the stimulation adverse effects</b>				
Headache	1.66(0.17)	1.34(0.12)	$t(80) = 1.51$	0.135
Nausea	1.07(0.04)	1.22(0.10)	$t(80) = -1.33$	0.187
Skin irritation under the electrode	2.22(0.21)	1.73(0.17)	$t(80) = 1.83$	0.072
Relaxed	2.95(0.27)	3.46(0.31)	$t(80) = -1.23$	0.222
Vigilant	2.76(0.25)	2.83(0.27)	$t(80) = -0.20$	0.845
Unpleasant feelings	2.07(0.23)	1.95(0.17)	$t(80) = 0.42$	0.676
Dizziness	1.54(0.16)	1.71(0.21)	$t(80) = -0.65$	0.520
Neck pain	1.05(0.03)	1.24(0.10)	$t(80) = -1.79$	0.077
Muscle contractions in the neck	1.56(0.17)	1.59(0.20)	$t(80) = -0.09$	0.926
Stinging sensation in the ear	3.22(0.29)	3.71(0.30)	$t(80) = -1.18$	0.243

692

693 **Figure legends**

694

695 **Fig. 1** Schematic illustration of experimental protocol and data analysis. A, Procedure  
696 timeline. B, Drift Diffusion Model framework. C, Overview of dynamic functional  
697 connectivity (dFC) analysis.

698

699 **Fig. 2** taVNS effects on behavioral index. A, Accuracy of No-Go response (mean  $\pm$   
700 SEM) under two treatment groups. B, Computed Hierarchical Bayesian estimation of  
701 the Drift Diffusion Model (HDDM) parameter differences between treatment groups.  
702 C, Drift rate of Go response mediated taVNS effects on the accuracy of No-Go  
703 response. \*  $p < .05$ . \*\*  $p < .01$ , \*\*\*  $p < .001$ , ns: no significant difference.

704

705 **Fig. 3** HDDM simulation results. Representative plot of observed vs. simulated  
706 responses (i.e., accuracy and reaction times) across taVNS and sham condition.  
707 Columns 1 and 3 represent probability densities. Columns 2 and 4 represent  
708 percentage of correct responses in each reaction time quantile. Obs = observed. Sim =  
709 simulated. Corr = correct. Incorr = incorrect.

710

711 **Fig. 4** fNIRS results. A, HbO differences of bilateral IFG for inhibition on angry and  
712 happy faces under taVNS and sham treatment. B, Different effects of treatment on  
713 FCs in determined State 1, State 2, State 3, and State 4 respectively, red line/box:  
714 taVNS > sham; blue line/box: taVNS < sham. C, Mediation analysis between  
715 treatment, FC between IFG and OFC, and accuracy of No-Go response. D, Parallel  
716 mediation analysis between treatment, FC between IFG and OFC, drift rate for Go  
717 stimuli and accuracy of No-Go response. FC-functional connectivity; IFG-Inferior  
718 frontal gyrus; OFC- Orbitofrontal cortex. \*  $p < .05$ , \*\*  $p < .01$ , \*\*\*  $p < .001$ .

719

720

721